Περίληψη:
Context. Cardiovascular risk is increased in women with polycystic ovary
syndrome (PCOS). Do insulin sensitizing agents such as metformin (MET)
and myoinositol (MI) ameliorate biomarkers of cardiovascular risk?
Objective. To compare the effects of MET and MI on blood pressure, lipid
profile and high sensitive C-reactive protein (hs-CRP) in women with
PCOS in respect to their body mass index (BMI).
Design. Open label, parallel randomized, single center study.
Subjects and Methods. Sixty six women with PCOS (33 normal-weight and 33
overweight/obese) were randomized to either MI (4 g/day) or MET (1500
mg/day) for a period of 6 months. Serum concentration of hormones, lipid
profile, oxidized LDL (ox-LDL), hs-CRP, blood pressure measurement and
clinical assessment of BMI, waist circumference (WC) and Ferriman
Gallwey score (FG score) were performed before and after treatment.
Results. Thirty patients in each group completed the trial. Compared
with MET, MI significantly decreased diastolic blood pressure (DBP)
(p=0.036) and significantly increased serum hs-CRP (p=0.043). No
differences between groups in total cholesterol (TC), HDL-cholesterol,
LDL-cholesterol, ox-LDL and triglycerides were reported after 6 months.
Treatment with MI reduced BMI (p=0.037), WC (p=0.005), DBP (p=0.021) and
TC (r=0.008). During MET treatment a significant decrease in BMI
(10.005), WC (p=0.004), FG score (p=0.001), testosterone (p=0.013) and
free androgen index (FM) (p=0.006) was observed.
Conclusions. Our study showed an advantage of MI in reduction of DBP and
TC thus predicting favorable metabolic and cardiovascular outcomes in
PCOS women. MET more effectively decrease indices of hyperandrogenism.
Συγγραφείς:
Soldat-Stankovic, V
Pejicic, S. Popovic
Stankovic, S. and
Jovanic, J.
Bjekic-Macut, J.
Livadas, S.
Ognjanovic, S. and
Mastorakos, G.
Micic, D.
Macut, D.
